News Archive | Page 3 of 10 | Breakthrough T1D

The Sun Life Ride to Defeat Diabetes for JDRF Brings Corporate Canada Together to Move Work Aside and Move for a Cure for Type 1 Diabetes

October 1, 2023

Canada-wide, October 1, 2023 – One of Canada’s longest running and top fundraising events will be taking place in Montréal, QC, Toronto, ON and Calgary, AB on October 5, 12 and 19, respectively. The Sun Life Ride to Defeat Diabetes for JDRF is a high-energy event that sees hundreds of corporate executives and teams shed their business wear for workout clothes to pedal for a cure for type 1 diabetes (T1D).
Participants from corporate Canada will take part by spinning on hundreds of stationary bikes set up in three major cities. Additional events are being coordinated in corporate headquarters, gyms, and spin studios across the country as supporters Ride in support of JDRF throughout the month of October, towards our ultimate finish line: a world without T1D.

T1D is an autoimmune condition impacting almost 300,000 Canadians. Since the Ride launched in 1988, corporate Canada has raised millions of dollars to accelerate the pace of T1D research. Due to advances in research over the past five decades, approximately 25 years have been added to the lifespan of a person living with T1D and receiving the latest care.

“The Ride is an exciting team building event that lets people take a break from their offices, Zoom and Teams meetings, to pedal for a cure alongside their colleagues in support of people living with type 1 diabetes. People are eager to come together, so we are thrilled to be expanding this year, with events in Montréal and Toronto, and now Calgary, says Dave Prowten, CEO of JDRF Canada. “We are grateful that Sun Life and corporate Canada will move their work aside and move us closer to a cure for type 1 diabetes by helping us reach our $2.6 million fundraising goal.”

Sun Life has been a proud supporter of the Ride since 2017, and in 2019 they became the national title sponsor.

“Diabetes is a growing disease that affects millions across the world,” said Dave Jones, President, Sun Life Health. “With more than 300,000 Canadians currently living with type 1 diabetes, we’re committed to helping them live healthier lives. Thank you to JDRF for their continued effort in searching for a cure and positively impacting the lives of those affected by diabetes.”

-30-

About JDRF

JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, governments, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout Canada and five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit breakthrought1d.ca.

Sun Life in the Community

Sun Life is sustainability-driven, focusing on areas where it can have the greatest impact. By actively supporting the communities in which Sun Life lives and works, the organization can help build a positive environment for Clients, employees, advisors, and shareholders. Physical health and mental health are at the centre of our philanthropic support, with a focus on supporting programs and organizations that strive to empower people in Canada to live their healthiest lives no matter where they are in their journey. Sun Life employees and advisors take great pride in volunteering and giving back to make life brighter for individuals and families across Canada.

Learn more about Sun Life in the community

For more information:

Ruth Kapelus

National Content & Media Relations Manager, JDRF Canada

T. 647.789.2322

E. rkapelus@jdrf.ca

JDRF Canada and Diabetes Canada collaborate to close gaps in mental health support for Canadians with diabetes with launch of Mental Health + Diabetes Directory

September 12, 2023

September 12, 2023 – Canada-wide – Mental health matters. Especially for those living with diabetes, a chronic condition affecting more than 4 million Canadians.

Diabetes can be a very challenging condition to live with, often requiring constant planning and vigilance, but a strong support network and the right care help to reduce the burden. However, it isn’t always easy to find the necessary support, especially when it comes to mental health.

To better help address some of the many gaps in mental health support for people with diabetes, in 2021, JDRF Canada launched a Mental Health Strategy to fund research, train mental health providers, and engage and educate healthcare providers and the type 1 diabetes community on mental health. Collaborations and partnerships with organizations like Diabetes Canada and others working in the areas of diabetes and mental health has been crucial to see the strategy develop and be realized.

The Mental Health + Diabetes Training Program, designed and implemented by JDRF Canada in collaboration with Diabetes Canada, aims to help to fill a gap in Canadian health systems. This bilingual program, launched in late 2022, provides knowledge and tools to help registered Canadian mental health providers deliver the best support to their clients with type 1 or type 2 diabetes, and expand the capacity of health systems to meet this currently underserved need.

As a result, JDRF Canada, in collaboration with Diabetes Canada is able to launch the Mental Health + Diabetes Directory. The Directory is intended to act as a connection tool, to provide people living with or affected by diabetes with access to information about registered mental health providers who have engaged in additional training to provide mental health support specific to addressing the realities of living with diabetes. Every mental health provider included in the Directory has successfully completed the Mental Health + Diabetes Training Program. The Directory will continue to expand as more mental health providers are trained.

Both the Training Program and Directory will help to close gaps in both the delivery of and access to mental health supports for those living with diabetes across Canada.

Dr. Sarah Linklater, Chief Scientific Officer – JDRF Canada
“Through the Mental Health + Diabetes Training Program and now the launch of the Directory, JDRF Canada aims to increase the capacity of Canadian mental health providers to support people with diabetes and, in turn, improve their quality of life and health outcomes. Working together with Diabetes Canada will allow us to expand the reach of these initiatives and we continue to be so grateful for their support and collaboration.”

Laura Syron, CEO & President – Diabetes Canada
“As someone who lives with diabetes, I know first-hand the strain this chronic condition can place on your mental and emotional health. Through innovative partnerships like this one with JDRF, Diabetes Canada is proud to play a role in building better mental health supports and care for people living with diabetes in Canada. This directory will empower health-care providers to address the holistic needs of their patients and provide them with the resources and tools to live well with their condition.”

Monica Murray, M.Ed. (OACCPP), RP
“The upcoming launch of The Mental Health + Diabetes Directory is an exciting initiative from JDRF Canada and Diabetes Canada. This directory will feature professionals who understand the complexities associated with this chronic disease since they have all completed extensive training on the diabetes-specific challenges experienced by clients with type 1 or type 2 diabetes. The Mental Health + Diabetes Directory will be an excellent resource for clients with diabetes and for their family members as well.”

Henri Ng-Wan, CRHA
When I received my diagnosis, I remember having a tough time accepting my new reality. After a few months, I got the courage to ask my endocrinologist for a referral and even though she wanted to help me, she was not able to give me any reference as she was also struggling to find mental health specialists for other patients. The same thing happened when I reached out to a Quebec-based association whose mission is to support people living with diabetes. The directory responds to the needs of our community and was a missing tool for our healthcare professionals.

About JDRF Canada 
JDRF Canada is the leading charitable organization funding type 1 diabetes (T1D) research in Canada. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, governments, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout Canada and five international affiliates are dedicated to advocacy, community engagement and our shared vision of a world without T1D. For more information, please visit breakthrought1d.ca

About Diabetes Canada

A world free of the effects of diabetes is our vision. That’s why we’re working together to improve the quality of life of people living with diabetes. We’re sharing knowledge and creating connections for individuals and the health-care professionals who care for them; advocating through public policy; and funding research to improve treatments and find a cure to end diabetes.  

Media Contacts
Ruth Kapelus
National Content and Media Relations Manager, JDRF Canada
T. 647.789.2322
E. rkapelus@jdrf.ca
235 Yorkland Blvd., Suite 600 Toronto, ON M2J 4Y8
breakthrought1d.ca

Leah Siversky
Senior Manager, Communications & Public Relations
T: 416.408.7041
E: leah.siversky@diabetes.ca
1300-522 University Ave., Toronto, ON M5G 2R5
diabetes.ca

British Columbia expands public coverage of type 1 diabetes technologies to include a flash glucose monitoring device

August 2, 2023

August 2^nd, 2023 – British Columbia – The Government of British Columbia announced yesterday that the FreeStyle Libre, a flash glucose monitoring (Flash GM) device, will be covered by BC PharmaCare as a limited-coverage benefit for people living with type 1 diabetes (T1D) beginning August 1^st 2023.

Prior to this announcement, public coverage in British Columbia was limited to only the Dexcom G6 continuous glucose monitor (CGM).

JDRF is a strong proponent of equitable access to a variety of T1D technologies, including pumps, CGMs and Flash GMs. People living with T1D deserve to be able to choose which device is most suitable to both meet their health needs and best manage their disease. Yesterday’s announcement improves patient choice by adding another device that is publicly covered for British Columbians living with T1D.

In British Columbia, it is estimated that 34,000 people live with T1D. For these individuals, managing their condition daily involves monitoring their blood glucose levels and administering insulin through injections or insulin pumps. Each insulin dosage needs to be meticulously tailored, taking into account their carbohydrate intake and physical activity. Despite this careful management, people with T1D still remain vulnerable to a variety of serious complications such as kidney disease, vision impairment, amputation, and even death.

Use of devices like Flash GMs have been shown to reduce hospitalizations and the risk of longer-term complications for its users. They also help to ease some of the anxiety from living with T1D by allowing individuals to better plan activities around the disease including exercise, meals, and rest. These devices are not simply a luxury – they are lifesaving technologies.

Through its #AccessForAll advocacy campaign, JDRF Canada has been working to help make a variety of T1D technologies affordable and accessible for all Canadians living with the disease. In doing so, this campaign works to improve lives by helping to alleviate the financial, physical, and mental health burdens associated with T1D.

“JDRF Canada celebrates the announcement from British Columbia to offer greater patient choice to those living with type 1 diabetes. By introducing a flash glucose monitor into its coverage, the Government of British Columbia recognizes the value of proper diabetes management and how diabetes technology can benefit not just the patient, but also the healthcare systems that support them. We applaud this decision to enable safer and healthier lives for everyone living with type 1 diabetes” says Dave Prowten, CEO of JDRF Canada.

In 2022, JDRF commissioned a cost effectiveness study to support advocacy efforts towards expanded provincial public coverage. The study examined population level impact on diabetes-related complications, mortality, and cost effectiveness of the three glucose monitoring techniques used by adults with T1D in Canada. While provincial coverage of these devices represents a high short-term investment, it is overshadowed by significant long-term cost savings due to reduced complications, hospitalizations, and additional medical interventions.

Since 2019, JDRF’s Access for All campaign has engaged passionate advocates from T1D communities across the country with proven results. With support from JDRF, they are making their voices heard and has driven change in several provinces and territories to improve access.

Read the government release here.

About JDRF Canada

JDRF Canada is the leading charitable organization funding type 1 diabetes (T1D) research in Canada. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. Since our founding in 1974, JDRF has invested more than $80 million CDN in research funding. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, governments, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout Canada and five international affiliates are dedicated to advocacy, community engagement and our shared vision of a world without T1D. For more information, please visit breakthrought1d.ca.  

For more information:

Monica Kocsmaros
Chief External Relations Officer
T. 647.354.5598
E. mkocsmaros@jdrf.ca
235 Yorkland Blvd., Suite 600, Toronto, ON M2J 4Y8
breakthrought1d.ca

JDRF Announces Dave Prowten to Retire, Announces Jessica Diniz as Successor

June 23, 2023

Helena Gottschling, Chair of the JDRF Canada Board of Directors is pleased to announce the appointment of Jessica Diniz as their next President & CEO, effective January 1, 2024.

“We congratulate Jessica on her appointment and will benefit from her depth of experience in the non-profit sector, passion for the cause and fundraising experience” says Helena Gottschling. “The board is confident that Jessica is the right leader at the right time to help us build on successes to-date and drive our mission forward.”

Dave Prowten, who has led the organization for over 10 years as President & CEO will be retiring at the end of 2023 and he is looking forward to spending more time with his family. His leadership has been instrumental in increasing JDRF’s mission impact, extending research partnerships and passionately advocating for all Canadians living with T1D.

“On behalf of the Board, I would like to extend our deepest gratitude to Dave for his exceptional leadership and dedication to JDRF as President & CEO”, says Helena Gottschling.

Dave’s legacy includes establishing critical partnerships with government, partners and other diabetes organizations to further our mission, significantly improving the reimbursement landscape for all Canadians living with type 1 diabetes and representing the T1D community with conviction at every opportunity. It is now an exciting time to pass the torch over to his successor to build on the momentum JDRF has been experiencing and create lasting impact for the type 1 diabetes community.

Jessica Diniz is a seasoned senior executive with over 20 years’ experience in strategic fundraising and leading high-performance teams. Jessica joined JDRF in 2015, where she has led the strategy to pivot JDRF from being events-based, to a highly impactful, effective fundraising organization. Most recently, Ms. Diniz launched JDRF’s largest major gift campaign to-date, the JDRF’s $100M Campaign to Accelerate in 2020, shifting the organization to a donor-centred fundraising model. Prior to her time at JDRF, Jessica held senior roles at both Sunnybrook Foundation and Cystic Fibrosis Foundation.

“I am thrilled to take on this new challenge. In the past few years, JDRF has undergone transformational change in driving more dollars to its mission. I am excited to build on this momentum and continue to ask – how do we help Canadians living with T1D, in the most impactful way. It will be an honour to work alongside the incredibly talented JDRF staff, and deeply passionate and skilled volunteers towards this goal.” – Jessica Diniz

“It has been a privilege to lead JDRF and serve the passionate type 1 diabetes community. This is an incredibly exciting time in type 1 diabetes research and Jessica brings tremendous experience and extraordinary commitment, and I am confident she will lead JDRF to new heights and accelerate our mission.” – Dave Prowten

For more information:
Monica Kocsmaros
Chief External Relations Officer
E: mkocsmaros@jdrf.ca
T: 647 354 5598

Celebrating 30 years of the Sun Life Walk to Cure Diabetes for JDRF

June 1, 2023

Throughout June more than 40 communities will be gathering across Canada to raise funds for type 1 diabetes research

The Sun Life Walk to Cure Diabetes for JDRF is the largest fundraising event in Canada that brings together the type 1 diabetes (T1D) community to raise funds for T1D research. A fun-filled family and community celebration, the Walk has raised more than $137 million to date making it one of the longest running and most successful fundraising events in Canada.

Throughout the month of June, more than 40 Walk events will be held across the country. The collective fundraising goal is $3.1 million that will go towards research into cures for this disease. This year is the 30th anniversary of the Walk and JDRF is proud to celebrate three decades of progress, commitment, and improving lives for people affected by T1D.

T1D is an autoimmune disease that affects close to 300,000 Canadians. For over 100 years, the only available treatment has been insulin, and even with careful management there is the risk of diabetes-related complications like kidney failure, blindness, amputation and even death. Canada has one of the fastest-growing rates of diagnosis in the world, and we don’t know why. There is currently no disease-modifying therapy and no cure. Continued investment in groundbreaking research, such as stem cell-based treatments that can produce insulin in those living with the disease, is crucial for improved treatments and cures.

“There is nothing quite like the Walk. It is truly inspiring to see the passion and dedication of our type 1 diabetes families and their resolve to both support each other and help us get closer to a world free from this disease,” said Dave Prowten, President and CEO of JDRF Canada. “We have seen so much progress in type 1 diabetes research over the past 30 years, from new devices and technology, to significant advances in stem cell therapies, and developments in screening that mean we may one day be able to stop the disease before it can even start. Funds raised from the Sun Life Walk to Cure Diabetes for JDRF will help to accelerate the pace of the most promising type 1 diabetes research.”

Abbott’s Diabetes Care division has returned as the Walk’s National Premiere Partner.

“At Abbott, we continually strive to make a meaningful difference and improve the health and quality of life for Canadians living with diabetes,” says Marie-Flore Nabor, Divisional Vice President, Canada-Latin America Region, Diabetes Care. “This commitment extends beyond our life-changing technologies to include long-standing partnerships and support for JDRF and the families of those living with type 1 diabetes.”

Sun Life has been a national sponsor of the Walk since 2014 and national title sponsor since 2018.

“With diabetes on the rise in Canada, it’s important to continue to focus on prevention, care, research and building awareness for the disease,” said Dave Jones, President, Sun Life Health. “The JDRF Walk is a long-standing fundraiser that helps bring people from across Canada together to raise funds for those living with type 1 diabetes. It’s programs like these that help build healthier and more sustainable communities.”

Learn more about the 2023 Sun Life Walk to Cure Diabetes for JDRF and help us move T1D research forward faster: jdrfwalk.ca

About JDRF

Sun Life in the Community

Learn more about Sun Life in the community

About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott- on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

For more information:

Ruth Kapelus
National Content & Media Relations Manager, JDRF Canada
T. 647.789.2322
E. rkapelus@jdrf.ca

JDRF Canada launches advocacy campaign for type 1 diabetes device (T1D) access

May 3, 2023

Working with local volunteers the non-profit hopes to get T1D on the agenda in the runup to the provincial election

ALBERTA— May 1, 2023 – JDRF Canada is recommending that candidates in the upcoming provincial election support Albertans living with type 1 diabetes (T1D) by expanding coverage of continuous glucose monitors (CGM) devices to all ages.

The organization also urges the government to expand coverage to include Flash Glucose Monitoring (Flash GM) devices for all ages. Funding these devices will reduce financial and physical burdens on Alberta’s health care system, offer greater patient choice and suitability of device, and further advance the government’s efforts to reduce wait times and improve health outcomes through the increased use of virtual care.

T1D is an autoimmune condition and one of the fastest-growing chronic health conditions, impacting nearly 25,000 Albertans. Certain factors like family history can increase risk, but it is not caused by lifestyle factors. T1D attacks the cells in the pancreas responsible for making insulin, meaning someone with T1D cannot convert food into energy. Insulin must be administered externally and continually balanced against food, rest, and activity. Even with the most careful management, T1D can lead to long-term complications including damage to the kidneys, eyes, nerves, heart and even premature death. There is currently no cure for T1D.

T1D is a lifelong disease and does not stop at 18 years of age, and neither do the complications and costs associated with managing this disease. By restricting CGM coverage to only those that are 18 years of age or younger, young adults and vulnerable persons are further financially burdened with the costs associated with this disease.

Other provinces such as Manitoba, Ontario, Quebec, PEI, and Yukon have all implemented some coverage for those beyond 18 years of age for either CGM or Flash GM devices, and in some cases both.

The out-of-pocket cost per year for the average Albertan without the devices can be as high as $6557. While there is an upfront cost to funding these devices, having access to glucose monitoring and insulin pumps has been proven to save healthcare costs in the long-term. Diabetes complications are significant drivers of health care spending.

Diabetes Canada has pegged the annual cost of health care spending due to diabetes in Alberta at $494 million in 2022 and is estimated to reach $692 million by 2032. While T1D accounts for a fraction of this spending, significant savings can be realized through better management of T1D, which will ultimately keep patients out of hospitals and enable them to better manage life with this disease.

In 2022, JDRF commissioned a cost effectiveness study on the use of advanced glucose monitors and determined that they are at much lower cost-effectiveness threshold than the acceptable threshold for decision-makers

“JDRF Canada, through its Access for All program, advocates governments for funding that we know will improve the lives of those living with type 1 diabetes, while we fund the most promising research into cures. Type 1 diabetes does not end at age 18 and it is a relentless, lifelong disease that requires continual self-management to survive,” says Dave Prowten, President and CEO of JDRF Canada.

“Type 1 diabetes is a non-partisan issue and we implore all parties in Alberta to recognize this and the value of innovation in diabetes technology by removing age caps on access to insulin pumps and advanced glucose monitors. Coverage of this critical technology will enable everyone living with type 1 diabetes to live healthier, safer and easier lives,” he continues.

Ensuring the most innovative diabetes devices are accessible to Albertans living with T1D means they can benefit from advancements in technology such as a hybrid closed loop system where an advanced glucose monitor can communicate with an insulin pump to change minute-to-minute insulin delivery based on changes in blood glucose levels. This system not only reduces the constant burden of self-management, but evidence shows that used a closed loop system significantly improves health outcomes, reduces the number of diabetes complications and hospitalizations, and reduces the risk of death.

“My T1D didn’t stop when I turned 18 and neither should provincial coverage of CGMs. It’s more than just the cost savings for the healthcare system, these devices help give people like me peace of mind.” – Kurtis Samagalski, a young adult living with T1D in Edmonton, Alberta

To become an advocate and join the campaign, please click here.

Making life with #T1D healthier, safer, and easier.
#AccessForAllAB

Government policies up to 2022

In July 2022, the government reversed its decision to change the Insulin Pump Therapy Program and will instead add additional pumps to its coverage. The government also established a diabetes working group and any decision on treatment for diabetes will be informed by the group.
In July 2021, the government announced increased coverage up to $2,400 for diabetes supplies in government sponsored programs, including Blue Cross Coverage for Seniors and Non-Group Coverage.
In December 2019, the government launched its Biosimilars Initiative which introduced changes for adults using insulin. To maintain public coverage, Individuals using an originator insulin will be required to switch to its biosimilar.
In February 2019, the Guidelines for Supporting Students with Type 1 Diabetes was released to offer guidance to provincial school boards.
In 2016, the Diabetes, Obesity and Nutrition Strategic Clinical Network (DON SCN) released an Inpatient Diabetes Management Initiative in its effort to standardize how patients with diabetes are cared for in Alberta’s hospitals.
In 2014, DON SCN released a provincial Diabetes Foot Care Clinical Pathway for Albertans with diabetes in its effort to reduce diabetic foot ulcers and amputations.

For more information:
Luka Stevanovic
National Director, Government Relations & Advocacy
T. 647-951-1978
E. lstevanovic@jdrf.ca
breakthrought1d.ca

Diabetes in Nova Scotia: Op-Ed

April 19, 2023

I was recently diagnosed with type 1 diabetes (T1D) at the age of 24. It wasn’t a disease that I knew much about, but it is one that is now going to change my life. T1D is an autoimmune condition where my body’s immune system mistakenly destroys insulin-producing cells in my pancreas. The hormone insulin allows my body to use sugar (glucose) from carbohydrates in the food I eat. Without this function naturally occurring in my body, I cannot properly regulate blood glucose levels. This can lead to me suffering from hypoglycemic or hyperglycemic events that can lead to life threatening complications.

Managing T1D is a 24/7 job without any breaks. I require multiple injections of insulin each day to survive. And it’s not just one type of insulin. I have long-acting insulin which is meant to mimic the body’s natural insulin production, and short-acting insulin which is administered when I eat to correct high blood sugar levels. This means I also need to count the carbs I eat to ensure I can accurately measure how much insulin I need at mealtimes.

Some people are fortunate to be on an insulin pump, which is a small, computerized device often worn on a belt or in a pocket that is attached to the body through a small needle inserted into the skin. The pump delivers a continuous low (basal) dose of insulin. And when a person eats, they push a button on the pump to deliver an extra amount of insulin called a bolus to provide insulin for their food.

But it doesn’t stop there. I also need to check my blood-sugar levels throughout the day with several fingerpicks. However, there are advanced glucose monitors that do this automatically for you. A flash glucose monitor (Flash GM) is a small sensor worn under your skin, which measures your blood glucose levels continuously throughout the day and night. You find out your levels by scanning the sensor whenever you want to.

Similarly, a continuous glucose monitor (CGM) is a sensor just under the skin that measures the tissue-glucose levels in real time. The levels are then relayed to a receiver, smartphone or insulin pump which displays the readings. This also means if my blood sugars go too high or too low when I’m sleeping, an alarm will go off alerting me, or anyone else who received my readings. This means I can sleep throughout the night without worrying that I’ll suffer from my blood sugars going way out of range.

All these devices allow greater flexibility with meals, exercise and daily schedule; improved physical and psychological well-being; smoother control of blood-glucose levels and they enable virtual care, allowing my healthcare providers to see what is happening inside my body without me needing to physically be in an office.

While these devices are life-changing, they also come at a high cost without private or public coverage. That’s why I was anxiously awaiting the 2023 budget out of Nova Scotia, hoping to see T1D devices finally covered – but they weren’t. Disappointment does not come close to how I’m feeling. Without public coverage of these devices, I cannot access them.

Nova Scotia is now falling behind all other Atlantic provinces in this area, failing all Nova Scotians living with T1D. New Brunswick recently announced expanded coverage of devices by removing the existing age cap on the insulin pump program and adding CGMs to coverage. Newfoundland is now piloting a CGM project examining effectiveness and outcomes of this device. Last year, Prince Edward Island announced expanded coverage of Flash GMs and CGMs, now offering the most comprehensive coverage of devices in the Atlantic region and most of Canada.

The most frustrating part is we know that these devices are both cost effective and improve health outcomes. Last year, JDRF Canada commissioned a study to examine glucose monitoring systems, comparing Flash GM, CGM and self-monitoring of blood glucose (finger pricks). Not surprisingly, it noted that use of these devices leads to fewer complications, reduces long-term costs associated with hospitalization, leads to improved mortality rates AND are cost effective when looking at acceptable thresholds.

There was absolutely nothing that I did to become diabetic, but now have no choice but to do my best to survive every day with it. By providing increased public access and coverage for essential medical devices like Flash GMs/CGMs and insulin pumps, it would allow for people with diabetes, like myself, to thrive and manage this lifelong disease day to day with ease, rather than to go through each day without them.

Emma Perry

New Brunswick expands access to insulin pumps and continuous glucose monitors

March 21, 2023

March 21, 2023 – New Brunswick – The Government of New Brunswick achieved an important milestone today by announcing an investment of $2.1 million to improve access to diabetes devices. The province will be expanding the insulin pump program by removing the existing age cap, updating the family contribution calculation, and including coverage for continuous glucose monitoring. Prior to this announcement, insulin pump coverage in New Brunswick did not extend beyond age 25 and there was no public coverage for advanced glucose monitors. Further details of this expanded coverage, including eligibility, will be known at a later date.

JDRF Canada’s #AccessForAll campaign works to improve life for all Canadians living with type 1 diabetes (T1D) by making diabetes technology affordable and accessible. By encouraging greater public coverage, JDRF works with the type 1 diabetes (T1D) community to help reduce the out-of-pocket costs for life-sustaining technology. These devices help ease the financial, physical, and mental health burdens associated with the disease.

It is estimated that 7,900 people live with T1D in New Brunswick and daily management of blood glucose is essential to their survival. Constant monitoring of blood glucose is a reality of this disease and must be balanced with external insulin administered through injections or use of an insulin pump. Even with the most careful management, those living with T1D are at risk of serious diabetes-related complications such as kidney disease, blindness, amputation, and even death.

“JDRF Canada is thrilled with this announcement out of New Brunswick, which is improving the lives of those living with type 1 diabetes. As we all know, type 1 diabetes does not end at age 25 and it is a relentless, lifelong disease that requires continual self-management to survive. We applaud the Government of New Brunswick for recognizing this and the value of innovation in diabetes technology by removing age caps on access to insulin pumps and now providing coverage for advanced glucose monitors. Coverage of this critical technology will enable everyone living with type 1 diabetes, to live healthier, safer and easier lives,” says Dave Prowten, President and CEO of JDRF Canada.

Devices like insulin pumps and advanced glucose monitors not only make T1D self-management easier but has led to better health outcomes for its users. Insulin pumps provide greater control in the administration of insulin and continuous glucose monitors can display real-time readings of blood glucose levels including time in target range (TIR). Integrated technology allows them to be used together to form a hybrid-closed loop (HCL) system and acts as an artificial pancreas to allow automatic infusions of insulin based on real-time glucose trends.

Being able to monitor blood glucose in real-time significantly improves self-management and reduces hospitalizations and the risk of long-term complications. Users are also given relief from some of the anxiety associated with the disease as they can better control activities like exercise, meals, and rest.

A JDRF-commissioned cost effectiveness study in 2022 examined population level impact of glucose monitoring techniques on diabetes-related complications, mortality, and cost-effectiveness. It was proven that while introducing these devices under public coverage represents a high short-term investment, it pales in comparison to the significant long-term cost savings from reduced complications, hospitalizations, and medical interventions.

Through the Access for All campaign, JDRF is engaging with passionate T1D advocates across the country to advocate for those who pay out-of-pocket for life-saving technology due to lack of coverage in their provinces. Since its launch in 2019, the campaign has driven significant change in many provinces and territories but until a cure can be found, JDRF will continue to advocate for universal access to and patient choice for diabetes technologies for all those who need it.

“A CGM makes our daughter Mariah’s life with type 1 diabetes be as close to that of someone without T1D. Sleepovers, basketball, and just being with her friends are now possible without worrying about a serious life-threatening event”, say Robert and Louise Inglis, whose daughter Mariah lives with T1D.

“CGMs keep children with T1D safer every day and improve their long-term health. The added bonus is more sleep and less worry for these two working parents. CGM’s are good for kids, families, and our health care system”, they continue.

Read the government release here.

About JDRF Canada

For more information:

Monica Kocsmaros
Chief External Relations Officer
T. 647.354.5598
E. mkocsmaros@jdrf.ca
235 Yorkland Blvd., Suite 600, Toronto, ON M2J 4Y8
breakthrought1d.ca

JDRF Canada and Diabetes Canada collaborate to close gaps in mental health support to improve quality of life for Canadians with diabetes

March 15, 2023

Mental health matters. Especially for those living with diabetes, a chronic condition affecting more than 4 million Canadians, that requires countless decisions every day about food, rest, play and more.

Living with diabetes is a constant balancing act of planning nutrition, monitoring blood glucose, managing medications – and the fear from the risk of a myriad of potential diabetes-related complications, including blindness, kidney disease, amputation, and even early death.

People with diabetes are more likely to experience mental health challenges such as depression, anxiety and eating disorders and can benefit from interventions that prevent or treat these mental health conditions. But standard care for diabetes doesn’t always address mental health concerns when they exist, despite evidence that mental health challenges affect the physical management of the disease and can result in poorer quality of life and health outcomes. Moreover, few Canadian mental health providers have the necessary knowledge about diabetes to help properly address the unique mental health needs of people living with the condition.

In 2021, JDRF Canada launched a Mental Health Strategy that set out to address some of the many gaps in mental health support for people with diabetes through funding research, training healthcare providers, and developing community programs focused on mental health. Partnerships with organizations working in the areas of diabetes and mental health is crucial for the strategy to positively impact the diabetes community and their care providers.

The Mental Health + Diabetes Training Program, developed by JDRF Canada with the support of Diabetes Canada, was designed to help to fill a gap in Canadian health systems. This bilingual program, launched in late 2022, provides knowledge and tools to help registered Canadian mental health providers deliver the best support to their clients with type 1 or type 2 diabetes, and expand the capacity of health systems to meet this need.

Mental health providers who successfully complete the Mental Health + Diabetes Training Program will have the opportunity to join a new, publicly accessible Mental Health + Diabetes Directory, to be launched later in the year. The Directory will allow healthcare providers and people living with diabetes to be referred to trained providers who can offer specialized support specific to living with this chronic disease. 

This unique training program and upcoming directory will help to close gaps in both the delivery of and access to mental health supports for those living with diabetes.

Dr. Sarah Linklater, Chief Scientific Officer – JDRF Canada

“Most mental health providers have limited knowledge of the specific mental health impacts of diabetes, in many cases limiting opportunities for a productive and long-lasting connection with clients with diabetes.”

“Through the Diabetes + Mental Health Training Program and an upcoming associated provider directory, JDRF aims to increase the capacity of Canadian mental health providers to support people with diabetes and, in turn, improve their quality of life and health outcomes. These initiatives are part of JDRF Canada’s broader Mental Health Strategy, which also includes community support programs, and research funding specifically related to mental health and T1D. Working together with Diabetes Canada will allow us to expand the reach of these initiatives and we are very grateful for their collaboration.”

Laura Syron, CEO & President – Diabetes Canada

“As someone who lives with type 2 diabetes, I know first-hand the toll managing your diagnosis can take on your mental health and well-being,” says Laura Syron, CEO & President of Diabetes Canada. “For people living with diabetes struggling with anxiety, depression and often shame, this program will offer a critical lifeline and support system, and perhaps most importantly help them feel seen and heard.”

Monica Murray, Registered Psychotherapist, Ontario

The Mental Health + Diabetes Training Program provided me with pertinent information about the physical and mental health effects of both type 1 and type 2 diabetes. After completing all areas of the training including the e-learning modules and the live session, I feel confident to incorporate the comprehensive material into my private practice. The training can be applied to individuals and family members who are either coping with a new diagnosis or the lasting effects of these conditions. 

Jen Miller – parent of a child with type 1 diabetes

We haven’t received any mental health support from our diabetes clinic. I’ve spoken to other parents who are trying to navigate the system and trying to find some help for their kids. And it’s hard. There are not a lot of providers out there, especially on the public side, but even on the private side. I had a counselor recommended to me by another parent and the wait list to see that person is over a year and a half, and it’s on the private side. I’d like Cody (my son) to find it normal to speak to a counselor or to a psychologist about his life. And then when problems arise, it’ll be easy for him to talk to someone. But if I needed help now, it would be almost impossible to find it.

About JDRF Canada 

About Diabetes Canada

Media Contacts

Ruth Kapelus
National Content and Media Relations Manager, JDRF Canada
T. 647.789.2322
E. rkapelus@jdrf.ca
235 Yorkland Blvd., Suite 600 Toronto, ON M2J 4Y8
breakthrought1d.ca

Leah Siversky
Senior Manager, Communications & Public Relations
T: 416.408.7041
E: leah.siversky@diabetes.ca
1300-522 University Ave., Toronto, ON M5G 2R5
diabetes.ca

Huge win for continuous glucose monitor (CGM) and insulin pump coverage for people with type 1 diabetes in Manitoba

March 7, 2023

Manitoba is the first province to completely remove the age restriction for these live-saving diabetes devices

March 7, 2023 – Manitoba – On March 7, 2023, the government of Manitoba announced that it was investing $120 million in the Manitoba Pharmacare program in part to expand coverage of diabetes devices like insulin pumps and glucose monitors. The province said it will be expanding the program to include all adults who have been diagnosed with type 1 and type 2 diabetes and have a prescription. Prior to this investment, coverage for pumps in Manitoba stopped at age 18 and coverage for advanced glucose monitors stopped at age 25. This announcement comes after significant advocacy from the Manitoba T1D community, with support from JDRF Canada.

JDRF’s #AccessForAll advocacy campaign aims to make T1D technology affordable and accessible for all Canadians living with the disease. The goal is to reduce the out-of-pocket costs for these technologies and improve access for Canadians with T1D.

An estimated 6,800 people in Manitoba have T1D. Living with T1D means managing the disease through frequent checking of blood glucose levels, regular infusions of insulin, either by injection or through an insulin pump, and carefully adjusting each dose to balance against carbohydrate consumption and activity levels. And even with the most careful management, people with T1D can experience significant diabetes-related complications including kidney disease, blindness, amputation and even death.

With coverage of both insulin pumps and CGMs expanding, those living with T1D and can take advantage of integrations for a hybrid-closed loop (HCL) system, which acts as an artificial pancreas. An HCL system is any insulin pump able to automatically deliver basal insulin by using an algorithm and real-time CGM sensor glucose trends.

“JDRF Canada is thrilled with this announcement out of Manitoba, which is now a leading province in terms of coverage of type 1 diabetes devices. As we all know, type 1 diabetes does not end at age 25. It is a relentless, lifelong, chronic disease that requires continual self-management to survive. We applaud the Government of Manitoba for recognizing this and the value of innovation in technology such as hybrid closed loop systems and supporting everyone in the province living with type 1 diabetes. Coverage of this critical technology will enable everyone living with type 1 diabetes, to live the healthiest, safest, and easiest lives possible,” says Dave Prowten, President and CEO of JDRF Canada.

T1D self-management is simplified and improved through technologies such as insulin pumps, which allow a person to give themselves insulin as needed and with greater control, and CGMs which provide real-time readings that help to improve overall blood glucose (HbA1C) levels and time in target range (TIR). Both can help to keep people out of hospital and reduce the potential for longer-term complications. They also help to relieve some of the anxiety that surrounds the disease and allow people with T1D to better plan exercise, meals, and rest.

In 2022, JDRF commissioned a cost effectiveness study that demonstrated that provincial coverage of diabetes devices, while a higher near-term investment, generates significant long-term cost savings due to lower costs of complications, potential hospitalization, and additional medical interventions.

Access for All was launched in 2019 and has already driven major change. Working with powerful voices from across the country, the power of grassroots organization and advocacy has led to several provinces and territories revisiting their coverage and expanding access.

“My insulin pump takes some of the burden of diabetes away. It helps keep my blood sugar in range, allows me the freedom to be active and allows me the freedom of not taking multiple injections a day. The extended coverage of this technology is so important to the health, not only physical but mental as well to those living with diabetes. For people my age it means we can make choices about our education, careers and families of our own one day without the financial worry of how we will pay for the technology that keeps us safe,” says Miles Dyer, a teenager living with T1D.

“My teenage son does a terrific job of managing his diabetes through the combined use of a CGM and pump. As his parent, also living with type 1 diabetes, I worry about both the added financial implications and the quality of his diabetes management if he were to age out of these programs,” says Steve Dyer.

“The access to a CGM and insulin pump through extended coverage to adults gives me, and so many Manitobans, new hope and the ability to improve our long-term health with the aid of these devices. This should prove a good investment and save money as well as lives,” he continues.

Diabetes devices are not a luxury but lifesaving equipment. Removing the age restriction is a significant step towards universal access and patient choice.

Manitoba’s announcement makes it the gold-standard in Canada with regards to T1D access and should be a model for all other provinces to follow. This announcement marks a significant accomplishment in increasing access to life-changing technology used in the management of T1D, and it is our hope that other provinces will be inspired by the leadership of Manitoba and begin to provide the same level of coverage.

Read the government release here.

About JDRF Canada

For more information:

Monica Kocsmaros
Chief External Relations Officer
T. 647.354.5598
E. mkocsmaros@jdrf.ca
235 Yorkland Blvd., Suite 600, Toronto, ON M2J 4Y8
breakthrought1d.ca

JDRF Canada is pleased to announce support of 7 trainees in the field of type 1 diabetes (T1D) in partnership with the Canadian Islet Research and Training Network

January 25, 2023

These training awards will support health researcher training to build capacity in the future of T1D research.

CIRTN was established in 2020 as a world-class training and research network with joint contributions from the University of Alberta, University of British Columbia, University of Manitoba, Université de Montréal, Institut de Recherches Cliniques de Montréal, and the University of Toronto and now includes 12 institutions from across Canada. 

Now, in 2023, JDRF Canada has partnered with CIRTN to leverage funding to this network from the National Science and Engineering Research Council – Collaborative Research and Training Experience (NSERC-CREATE) program. Through this partnership, JDRF Canada is pleased to fund 6 PhD trainee scholarships and 1 postdoctoral fellowship to trainees working on pancreatic islet research. This support is part of JDRF’s goal to expand its support of the next generation of T1D researchers in 2023 and beyond.

Angeles Olvera, Zuraya Elisa
PhD Student
Vincent Poitout, Université de Montréal

Mechanisms controlling beta cell proliferation by nutrients

Beta cells located within the pancreas are responsible for the production and secretion of insulin. T1D is caused by the destruction of beta cells by the body’s own immune response, whereas type 2 diabetes involves eventual loss of beta cell function. This research will examine how oleate (a fatty acid naturally occurring in animal and vegetable fats and oils) contributes to increasing the growth of beta cells. Specifically, the relationship between reactive oxidative species and antioxidant enzymes produced by the beta cells will be examined to determine its role in beta cell proliferation.

Wang, Yufeng
PhD Student
Jonathan Rocheleau, University of Toronto

Design of an islet-on-a-chip device to dynamically measure 1st-phase oxygen consumption rate and insulin secretion from individual islets

The measurement of insulin secretion and oxygen consumption rate by islets is important for characterizing glucose metabolism in people with diabetes. This research project will design an “islet-on-a-chip” – that is, a living islet stabilized inside a microfluidic chip – for the purpose of measuring insulin secretion and oxygen consumption from individual islets simultaneously. These devices will then be used to evaluate the impact of metabolic stresses on islets during glucose metabolism, providing new information about islet cell molecular function.

Kar, Saumadritaa
PhD Student
Bruce Verchere, University of British Columbia

Mitigating amyloid associated islet transplant failure with pramlintide-expressing human embryonic stem cell derived beta cells

Transplantation of insulin-producing beta cells is a potential curative therapy for T1D; however, limited organ donors, the need for lifelong immune suppression, and the eventual failure of transplanted cells hinder widespread clinical implementation. One cause of islet transplant failure is the formation of toxic protein aggregates called amyloid. Therefore, this research will examine the use of beta cells from genetically engineered embryonic stem cells. Specifically, these cells will be engineered to produce Pramlintide, which does not form amyloid, and assessed to determine whether the inhibition of amyloid formation could enhance transplant survival and function.

Velghe, Jane
PhD Student
Bruce Verchere, University of British Columbia

Characterizing human islet-resident macrophages in health and disease

Macrophages are innate immune cells that can alter their function based on their surrounding environment. In mice pancreas, islet macrophages play an important role in development and proliferation of insulin-producing beta cells, and thus are a potential target for diabetes therapy. This research project will analyze human islet macrophages to provide new insight into their function in T1D as well as the communication between macrophages and beta cells.

He, Siyi
PhD Student
Gareth Lim, University of Montreal/CRCHUM

Development of a screening approach to repurpose previously approved drugs to ameliorate Type I Diabetes

Autoreactive CD8+ T cells are the cells responsible for the selective destruction of insulin-producing beta cells in T1D. The survival of CD8+ T cells is controlled through specific protein-protein interactions. This research will identify compounds that can disrupt these protein-protein interactions – leading to destruction of the harmful CD8+ T cells. Small molecules that have destructive effects on CD8+ T cells may be a promising therapy for the delay or prevention of T1D with the additional benefits from small molecule drugs such as oral administration and lower cost as compared to existing therapies that target T cells.

Hoffman, Emily
PhD Student
Michael Riddell, York University

The role of somatostatin in the deficient glucagon response to acute and recurrent hypoglycemia

Glucagon is a pancreatic hormone that stimulates the liver to release stored glucose in response to low blood glucose levels as a counter-regulator to insulin, meaning that these two hormones work together to balance blood sugar. Somatostatin inhibits the release of insulin and glucagon, thus, blocking the action of somatostatin may help to prevent hypoglycemia in people with diabetes. ZT-01 is one such drug that acts in this way (i.e., a somatostatin receptor antagonist) and is now being tested in clinical trials for its ability to prevent lows in people with T1D by Canadian company Zucara Therapeutics. This project will delve further into the pathways affected by ZT-01 by studying somatostatin at low glucose levels in rodent models of type 2 diabetes, which will in turn help to inform and advance the ZT-01 development program.

Huang, Hui
Postdoctoral Fellow
Jean Buteau, University of Alberta

A novel small-molecule activator of Lyn kinase for the treatment of type 1 diabetes

Although people living with T1D have a substantial >80% loss of insulin-producing beta cell mass, there is evidence that most people with long-duration T1D still have surviving beta cells and secrete small amounts of insulin. Therefore, approaches that preserve residual beta cells and stimulate beta cell expansion may be a promising therapy for T1D. This research will examine a small molecule activator of Lyn – a novel regulator of beta cell “health”. Through pharmacological activation of Lyn, it is hypothesized that surviving beta cells will be preserved, and beta cell mass expansion will be promoted. This research will have significant implications for clinical therapies to harness existing insulin-producing beta cells in T1D.

JDRF Canada and Diabetes Canada are joining forces to accelerate diabetes research towards cures

January 25, 2023

JDRF Canada and Diabetes Canada are excited to announce how their combined funding efforts are helping to move diabetes research forward faster through support of two innovative projects focused on cutting-edge research on beta cells and islet replacement therapy.

These two projects, which are supported through the JDRF-CIHR Partnership to Defeat Diabetes, are being funded by CIHR, Diabetes Canada and JDRF Canada. The projects are five years in duration and involve a total diabetes research investment of $4 million.

Project 1: Designing stem cell-derived islets for diabetes therapy

Breakthroughs have been made in understanding the process by which islet cells develop naturally in the body. As a result, it is now possible to replicate many steps of this process in the laboratory with cultured stem cells, resulting in insulin-producing cells. Such cells are already being tested in clinical trials, with promising results, but much work remains to be done before islet replacement therapy is readily available in the clinic. In this project, a multidisciplinary team led by Dr. Timothy Kieffer, Professor at the University of British Columbia, aims to significantly improve upon the manufacturing of islet cells to achieve more robust insulin delivery, with a focus on mass-producing stem cell-derived islet cells.

Project 2: A deep phenotyping network for understanding human islet variation in health and diabetes

In this project, a research team led by Dr. Patrick MacDonald, Professor at the University of Alberta, is exploring how human islets function differently based on genetic and environmental factors, and how this variability impacts diabetes risk. The more we understand how various factors affect diabetes risk and islet dysfunction, the more opportunities will open to develop therapies for both type 1 and type 2 diabetes.

It’s never been a more exciting time in diabetes research, and the pace will only be accelerated with this collaboration of Canada’s leading diabetes organizations. We are confident this is an investment that will result in increased progress that will bring therapies from the lab to the diabetes community faster.

JDRF Canada

“JDRF is committed to a collaborative research funding approach, which we know helps accelerate the most promising diabetes research. We partner with academia, foundations, industry, government, and other non-profits like Diabetes Canada to collectively achieve our goal of improving the daily realities of people living with diabetes while working towards cures,” says Dr. Sarah Linklater, Chief Scientific Officer for JDRF Canada.

“We are thrilled to partner with Diabetes Canada and CIHR on these projects led by Dr. Kieffer and Dr. MacDonald, which have the potential to help us better understand the mechanisms of type 1 diabetes, and advance opportunities to treat the condition with stem cell-derived islets.”

Diabetes Canada

“Collaboration is essential to ensuring we harness the extraordinary potential of research and innovation to help improve the quality of life for people living with diabetes. That is why Diabetes Canada has committed to investing $1M into these projects over the next five years,” says Laura Syron, President and CEO of Diabetes Canada. “Canada is known for its world-class diabetes research, and we are proud to join JDRF Canada and excited for the promise and potential of Drs. Kieffer and MacDonald’s work.”

“We are very excited by the potential for stem cell derived islets to provide a source of regulated insulin in patients living with diabetes and are extremely grateful for this funding support by JDRF, CIHR and Diabetes Canada to enable our efforts to accelerate the development of this approach.”
– Dr. Timothy Kieffer

“Our project will provide a resource for diabetes research groups across Canada and internationally that will provide detailed information on the genetic, environmental, and nutritional factors that impact how well our bodies can make insulin,” said Dr. MacDonald. “Support of this work by Diabetes Canada, along with JDRF Canada and CIHR, will go a long way towards improving our understanding of why pancreas cells of some people make so much insulin, while others so little.”
– Dr. Patrick MacDonald

About JDRF Canada

About Diabetes Canada

Media Contacts:

Ruth Kapelus
National Content and Media Relations Manager, JDRF Canada
T. 647.789.2322
E. rkapelus@jdrf.ca
235 Yorkland Blvd., Suite 600 Toronto, ON M2J 4Y8
breakthrought1d.ca

Leah Siversky
Senior Manager, Communications & Public Relations
T: 416.408.7041
E: leah.siversky@diabetes.ca
1300-522 University Ave., Toronto, ON M5G 2R5
diabetes.ca